An arylsulfonamide that targets cell wall biosynthesis in <i>Mycobacterium tuberculosis</i>

We investigated the mechanism of action of an arylsulfonamide with whole-cell activity against <i>Mycobacterium tuberculosis</i>. We newly synthesized the molecule and confirmed it had activity against both extracellular and intracellular bacilli. The molecule had some activity against HepG2 cells but maintained some selectivity. Bacterial cytological profiling suggested that the mechanism of action was via disruption of cell wall synthesis, with similarities to an inhibitor of the mycolic acid exporter MmpL3. The compound induced expression from the IniB promoter and caused a boost in ATP production but did not induce reactive oxygen species. A mutation in MmpL3 (S591I) led to low-level resistance. Taken together, these data confirm the molecule targets cell wall biosynthesis with MmpL3 as the most probable target.

Authors

Institutions

Publication Details

Journal
Antimicrobial Agents and Chemotherapy
Published
2024-09-26
DOI
https://doi.org/10.1128/aac.01037-24
Citations
2
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis

Greg Durst, Joe Pogliano, Joseph Sugie, Diana Quach et al.
2 citations
Antimicrobial Agents and Chemotherapy
Tuberculosis Research and Epidemiology
0.78
article

An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis

Greg Durst, Joe Pogliano, Joseph Sugie, Diana Quach, Vanessa Pietrowski Baldin, Tanya Parish, Lauren Ames, Arielle Butts, R. H. Allen, Kenneth J. Henry
article en
2 citations

Abstract

We investigated the mechanism of action of an arylsulfonamide with whole-cell activity against <i>Mycobacterium tuberculosis</i>. We newly synthesized the molecule and confirmed it had activity against both extracellular and intracellular bacilli. The molecule had some activity against HepG2 cells but maintained some selectivity. Bacterial cytological profiling suggested that the mechanism of action was via disruption of cell wall synthesis, with similarities to an inhibitor of the mycolic acid exporter MmpL3. The compound induced expression from the IniB promoter and caused a boost in ATP production but did not induce reactive oxygen species. A mutation in MmpL3 (S591I) led to low-level resistance. Taken together, these data confirm the molecule targets cell wall biosynthesis with MmpL3 as the most probable target.

Antimicrobial Agents and ChemotherapyVol. 68(11)
Infectious Disease Research Institute (US), University of Washington (US), Syngenta (United States) (US)
Bill and Melinda Gates Foundation
Openalex Percentile: Top 27%
Tuberculosis Research and Epidemiology
0.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

An arylsulfonamide that targets cell wall biosynthesis in <i>Mycobacterium tuberculosis</i> — Greg Durst, Joe Pogliano, et al. · Antimicrobial Agents and Chemotherapy (2024) | TGRS Research Map | TGRS